Benitec Biopharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	-	-	-	0.08	0.07	0.06
Revenue Growth (YoY)	-	-	-	2.74%	23.73%	-42.16%
Gross Profit	-	-	-	0.08	0.07	0.06
Selling, General & Admin	34.74	23.43	6.99	6.38	6.65	6.51
Research & Development	19.2	18.33	15.61	12.77	11.27	7.02
Other Operating Expenses	-	-	-0.11	-	0.01	0.12
Total Operating Expenses	53.94	41.77	22.49	19.16	17.93	13.66
Operating Income	-53.94	-41.77	-22.49	-19.08	-17.85	-13.6
Interest Income	5.03	3.29	0.9	-0.03	-0.03	-0.01
Other Non-Operating Income (Expense)	0.02	0.56	-0.17	-0.45	-0.32	-0.28
Total Non-Operating Income (Expense)	5.05	3.85	0.74	-0.48	-0.35	-0.29
Pretax Income	-48.88	-37.92	-21.75	-19.56	-18.21	-13.88
Net Income	-48.88	-37.92	-22.37	-19.56	-18.21	-13.88
Net Income Attributable to Preferred Dividends	-	-	0.62	-	-	-
Net Income to Common	-48.88	-37.92	-22.37	-19.56	-18.21	-13.88
Shares Outstanding (Basic)	45	36	18	1	0	0
Shares Outstanding (Diluted)	45	36	18	1	0	0
Shares Change (YoY)	37.41%	97.17%	1225.16%	188.30%	90.24%	320.63%
EPS (Basic)	-0.93	-1.05	-1.22	-14.12	-37.88	-54.91
EPS (Diluted)	-0.93	-1.05	-1.22	-14.12	-37.88	-54.91
Shares Outstanding	34.35	26.25	10.09	1.67	0.48	0.48
Free Cash Flow	-19.82	-23.61	-19.58	-18.01	-15.91	-13.05
Free Cash Flow Per Share	-0.45	-0.65	-1.07	-13.00	-33.10	-51.66
Gross Margin	-	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-	-25441.30%	-24457.50%	-23044.10%
Profit Margin	-	-	-	-26082.70%	-24942.50%	-23528.80%
FCF Margin	-	-	-	-24017.30%	-21797.30%	-22123.70%
EBITDA	-53.46	-41.37	-22.15	-18.7	-17.46	-13.17
EBITDA Margin	-	-	-	-24933.30%	-23920.50%	-22325.40%
EBIT	-53.94	-41.77	-22.49	-19.08	-17.85	-13.6
EBIT Margin	-	-	-	-25441.30%	-24457.50%	-23044.10%

SEC Filings: 10-K · 10-Q